Neoadjuvant chemotherapy for gastric cancer: A meta-analysis of randomized, controlled trials

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 777-782

  Liao, Yi ^a   Yang, Zu Li ^a   Peng, Jun Sheng ^a   Xiang, Jun ^a   Wang, Jian Ping ^a  

^a THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gastric cancer; Meta analysis; Neoadjuvant chemotherapy; Randomized controlled trial

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN; TEGAFUR; URACIL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL EFFECTIVENESS; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE;

EID: 84876973555     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12152     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann. Oncol. 2003; 14: ii31-36.
3. Nashimoto A, Nakajima T, Furukawa H etal. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer. Japan Clinical Oncology Group 9206-1. J. Clin. Oncol. 2003; 21: 2282-2287.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
5. Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat. Rev. 2007; 33: 315-324.
6. Macdonald JS. Treatment of localized gastric cancer. Semin. Oncol. 2004; 31: 566-573.
7. Sant M, Allemani C, Santaquilani M etal. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur. J. Cancer 2009; 45: 931-991.
8. Yoshikawa T, Sasako M, Yamamoto S etal. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br. J. Surg. 2009; 96: 1015-1022.
9. Newman E, Marcus SG, Potmesil M etal. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J. Gastrointest. Surg. 2002; 6: 212-223.
10. Kelsen D, Karpeh M, Schwartz G etal. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J. Clin. Oncol. 1996; 14: 1818-1828.
11. Songun I, Keizer HJ, Hermans J etal. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur. J. Cancer 1999; 35: 558-562.
12. Cunningham D, Allum WH, Stenning SP etal. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355: 11-20.
13. Ychou M, Boige V, Pignon JP etal. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011; 29: 1715-1721.
14. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 1996; 17: 1-12.
15. Yonemura Y, Sawa T, Kinoshita K etal. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J. Surg. 1993; 17: 256-261.
16. Kobayashi T, Kimura T. Long-term outcome of preoperative chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. Gan to Kagaku Ryoho 2000; 27: 1521-1526.
17. Hartgrink HH, van de Velde CJ, Putter H etal. Neoadjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomized FAMTX trial. Eur. J. Surg. Oncol. 2004; 30: 643-649.
18. Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol. Rep. 2000; 7: 241-244.
19. Nio Y, Koike M, Omori H etal. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study. Anticancer Res. 2004; 24: 1879-1887.
20. Schuhmacher C, Schlag P, Lordick F etal. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J. Clin. Oncol. 2010; 28: 5210-5218.
21. Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag. Res. 2011; 3: 257-266.
22. Macdonald JS, Smalley SR, Benedetti J etal. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001; 345: 725-730.
23. Paoletti X, Oba K, Burzykowski T etal. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
24. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J. Gastroenterol. 2010; 16: 5621-5628.
25. Sym SJ, Chang HM, Ryu MH etal. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann. Surg. Oncol. 2010; 17: 1024-1032.
26. Webb A, Cunningham D, Scarffe JH etal. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophago-gastric cancer. J. Clin. Oncol. 1997; 15: 261-267.
27. D'Ugo D, Persiani R, Rausei S etal. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur. J. Surg. Oncol. 2006; 32: 1105-1109.
28. Shin SJ, Kim MK, Lee KH etal. The efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-fluorouracil based chemotherapy. Cancer Res. Treat. 2004; 36: 367-371.
29. Dikken JL, van Sandick JW, Maurits Swellengrebel HA etal. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011; 11: 329-337.